Terry A Jacobson1, Michael Miller2, Ernst J Schaefer3. 1. Office of Health Promotion and Disease Prevention, Emory University, Atlanta, Georgia, USA. Electronic address: tjaco02@emory.edu. 2. Division of Cardiology, University of Maryland Medical Center, Baltimore, Maryland, USA. 3. Tufts University, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Elevated triglyceride (TG) levels are prevalent among the US population, often occurring in persons who are overweight or obese, or who have type 2 diabetes or the metabolic syndrome. There is evidence that elevated TG levels may be a significant independent risk factor for coronary heart disease (CHD), particularly in women. OBJECTIVE: This article reviews data on the epidemiology, associated risks, treatment, and prevention of hypertriglyceridemia, including recommended TG goals and available TG-lowering agents. METHODS: MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids. The reference lists of relevant articles were examined for additional citations. Publications discussing the epidemiology of hypertriglyceridemia, CHD risk, treatment guidelines for lipid management, clinical trials involving TG-lowering drugs, and outcomes for lipid-modifying therapies were selected for review. RESULTS: Concern over the increasing rate of hypertriglyceridemia and its deleterious health consequences is reflected in the most recent National Cholesterol Education Program guidelines. Several lipid-lowering agents are available, including statins, fibrates, niacin, thiazolidinediones, and prescription omega-3 fatty acids. Clinical trials of these drugs have reported lowering of TG by 7% to 50%. Along with lifestyle changes, the use of combination pharmacotherapy to reduce lipid levels (including TG) may be an effective strategy in patients with dyslipidemia. CONCLUSION: Use of strategies to manage TG levels, along with low-density lipoprotein cholesterol levels, is warranted to help reduce the risk of CHD.
BACKGROUND: Elevated triglyceride (TG) levels are prevalent among the US population, often occurring in persons who are overweight or obese, or who have type 2 diabetes or the metabolic syndrome. There is evidence that elevated TG levels may be a significant independent risk factor for coronary heart disease (CHD), particularly in women. OBJECTIVE: This article reviews data on the epidemiology, associated risks, treatment, and prevention of hypertriglyceridemia, including recommended TG goals and available TG-lowering agents. METHODS: MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids. The reference lists of relevant articles were examined for additional citations. Publications discussing the epidemiology of hypertriglyceridemia, CHD risk, treatment guidelines for lipid management, clinical trials involving TG-lowering drugs, and outcomes for lipid-modifying therapies were selected for review. RESULTS: Concern over the increasing rate of hypertriglyceridemia and its deleterious health consequences is reflected in the most recent National Cholesterol Education Program guidelines. Several lipid-lowering agents are available, including statins, fibrates, niacin, thiazolidinediones, and prescription omega-3 fatty acids. Clinical trials of these drugs have reported lowering of TG by 7% to 50%. Along with lifestyle changes, the use of combination pharmacotherapy to reduce lipid levels (including TG) may be an effective strategy in patients with dyslipidemia. CONCLUSION: Use of strategies to manage TG levels, along with low-density lipoprotein cholesterol levels, is warranted to help reduce the risk of CHD.
Authors: Mario Kratz; David S Weigle; Patricia A Breen; Kaatje E Meeuws; Verna R Burden; Holly S Callahan; Colleen C Matthys; Jonathan Q Purnell Journal: J Investig Med Date: 2010-06 Impact factor: 2.895
Authors: E DeVallance; S Fournier; K Lemaster; C Moore; S Asano; D Bonner; D Donley; I M Olfert; P D Chantler Journal: Eur J Appl Physiol Date: 2016-03-03 Impact factor: 3.078
Authors: J J Dalal; R R Kasliwal; A L Dutta; J P S Sawhney; S S Iyengar; S Dani; N Desai; I Sathyamurthy; D Rao; A Menon; A Dasbiswas; G S Wander; M Chadha; M S Hiremath; D G Roy; V Gupta; N Shivakadaksham Journal: Indian Heart J Date: 2012-08-27